Medline (NASDAQ:MDLN) Stock Rating Reaffirmed as Buy by BTIG Research

Posted by Brian Himes on Nov 5th, 2026

Medline (NASDAQ:MDLN – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at BTIG Research in a research note issued to investors on Thursday, Benzinga reports. They presently have a $55.00 target price on the stock. BTIG Research‘s target price would suggest a potential upside of 36.31% from the stock’s previous close.

Other research analysts also recently issued reports about the stock. Weiss Ratings downgraded shares of Medline from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, October 8th. Citigroup raised Medline to a “strong-buy” rating in a report on Wednesday, August 5th. Mizuho cut their target price on shares of Medline from $48.00 to $45.00 and set an “outperform” rating for the company in a research report on Thursday, October 22nd. Truist Financial dropped their price objective on Medline from $56.00 to $47.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Finally, Robert W. Baird set a $42.00 price target on shares of Medline in a research note on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $46.54.

View Our Latest Stock Report on MDLN

Medline Stock Up 18.4%

Shares of NASDAQ MDLN opened at $40.35 on Thursday. The firm’s 50-day simple moving average is $34.58 and its 200 day simple moving average is $39.53. The company has a market cap of $53.05 billion and a price-to-earnings ratio of 51.08. Medline has a 12-month low of $31.37 and a 12-month high of $50.88. The company has a quick ratio of 2.61, a current ratio of 4.33 and a debt-to-equity ratio of 0.66.

Medline (NASDAQ:MDLN – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.12. The company had revenue of $7.86 billion for the quarter. On average, research analysts expect that Medline will post 1.49 earnings per share for the current fiscal year.

Insider Transactions at Medline

In other Medline news, major shareholder Private Ltd Gic sold 2,570,999 shares of the company’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $35.35, for a total value of $90,884,814.65. Following the completion of the transaction, the insider owned 20,231,483 shares in the company, valued at approximately $715,182,924.05. This represents a 11.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 8,538,960 shares of company stock valued at $302,807,442 over the last quarter. Company insiders own 0.81% of the company’s stock.

Institutional Investors Weigh In On Medline

A number of large investors have recently added to or reduced their stakes in MDLN. Janus Henderson Group PLC boosted its stake in Medline by 8.4% in the first quarter. Janus Henderson Group PLC now owns 11,451,861 shares of the company’s stock valued at $506,546,000 after acquiring an additional 887,240 shares during the last quarter. Banque Pictet & Cie SA lifted its holdings in shares of Medline by 2.0% during the third quarter. Banque Pictet & Cie SA now owns 7,455,089 shares of the company’s stock worth $258,692,000 after buying an additional 142,939 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its stake in Medline by 233.3% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 5,000,000 shares of the company’s stock worth $222,500,000 after buying an additional 3,500,000 shares in the last quarter. Bessemer Group Inc. grew its holdings in shares of Medline by 39,404.0% during the 1st quarter. Bessemer Group Inc. now owns 3,504,006 shares of the company’s stock valued at $155,929,000 after purchasing an additional 3,495,136 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in Medline by 30,255.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,700,425 shares of the company’s stock worth $94,353,000 after buying an additional 2,691,529 shares during the period.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

Positive Sentiment: Medline reported Q3 EPS of $0.44, versus the $0.32 consensus estimate, on revenue of $7.86 billion. Reports said the company raised its full-year growth outlook, helping drive a favorable market response to the results. Medline Q3 2026: EPS beats by 27%, full-year growth outlook raised Medline Q3 Net Sales Rise – Shares Up Pre-Bell
Positive Sentiment: Medline announced a $1 billion share-buyback program. Repurchases can support per-share results and signal management’s confidence, though the impact depends on timing and execution. Medline posts best intraday gain after Q3 beat, $1B share buybacks
Neutral Sentiment: The company plans to raise prices in 2027 to offset inflationary pressures. This may help protect margins, but the effect will depend on customers’ acceptance and Medline’s ability to manage costs. Medline plans to increase prices in 2027, reports strong Q3 results
Negative Sentiment: One report said quarterly profit fell, although Medline reaffirmed its FY2026 adjusted EBITDA outlook. The profit decline tempers the headline EPS beat. Medline Q3 Profit Falls, Reaffirms FY26 Adj. EBITDA Outlook; Shares Up
Negative Sentiment: A law firm announced an investigation into potential securities-law violations following reported product-quality concerns and stock drops. This is an allegation and investigation, not a finding of wrongdoing, but it adds legal and reputational uncertainty. MDLN Investigation Reminder

Medline Company Profile

(Get Free Report)

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.